Copaxone is still prescribed in 2025, although its use and coverage have undergone some updates and changes in recent times. It remains an option for treating multiple sclerosis (MS), particularly relapsing forms of the disease, but the landscape of MS treatment is evolving with newer therapies emerging.
As of 2025, Copaxone continues to be covered by various drug formularies and insurance plans, including Medicare and provincial drug benefit programs, but with specific criteria and codes that prescribers and pharmacists must follow. For example, in Ontario, Copaxone shares the same listing and usage criteria as similar glatiramer acetate products, and prescriptions now require updated codes to align with formulary changes made in August 2025. Existing prescriptions with older codes remain valid temporarily, but new prescriptions must comply with the updated system. This means that while Copaxone remains accessible, healthcare providers and patients need to be aware of administrative updates to ensure continued coverage and dispensing[1].
Clinically, Copaxone is still recognized for its role in reducing relapse rates in MS patients. Recent studies, including those focusing on pediatric MS, show that Copaxone can significantly reduce relapse rates compared to some other treatments like Avonex. However, there is a trend toward switching patients to higher-efficacy treatments when disease activity is not fully controlled by Copaxone. Nearly half of pediatric patients on Copaxone switched to more potent therapies within about 14 months due to partial disease control. This reflects a broader shift in MS management favoring early use of high-efficacy treatments to better prevent disability progression[2].
Insurance coverage for Copaxone remains in place in 2025, with many health plans including it on their formularies, often with prior authorization and quantity limits. For instance, Cigna’s Medicare plans list Copaxone as a covered drug with specific dosage forms and usage limits, indicating that it is still a recognized and reimbursed treatment option[4]. Similarly, other health plans and pharmacy benefit managers continue to include Copaxone in their drug lists, ensuring patient access under defined conditions[3][5].
In summary, Copaxone remains a prescribed and covered treatment for multiple sclerosis in 2025, but its use is increasingly balanced against newer, higher-efficacy therapies. Patients and prescribers must navigate updated formulary rules and codes to maintain access, and clinical practice is trending toward personalized treatment strategies that may involve switching from Copaxone to other agents if disease control is insufficient.
